<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CIDOFOVIR</span><br/>(cye-do'fo-ver)<br/><span class="topboxtradename">Vistide<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antiviral</span><br/><b>Prototype: </b>Acyclovir<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>75 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Cidofovir, a nucleotide analog, suppresses cytomegalovirus (CMV) replication by inhibiting CMV DNA polymerase.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Cidofovir reduces the rate of viral DNA synthesis of CMV. Cidofovir is limited for use in treating CMV retinitis in patients
         with AIDS.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of CMV retinitis in patients with AIDS.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to cidofovir, history of severe hypersensitivity to probenecid or other sulfa-containing medications, lactation;
         childbearing women and men without barrier contraception; pregnancy (category C); severe renal dysfunction. Safety and effectiveness
         in children not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal function impairment, history of diabetes, myelosuppression, previous hypersensitivity to other nucleoside analogs; older
         adults.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">CMV Retinitis: Induction</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 5 mg/kg once weekly for 2 wk. Also give 2 g probenecid 3 h prior to infusion and 1 g 8 h after infusion (4 g total).<br/><br/><span class="indicationtitle">CMV Retinitis: Maintenance</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 5 mg/kg once every 2 wk. Also give 2 g probenecid 3 h prior to infusion and 1 g 8 h after infusion (4 g total).<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 4155 mL/min: 2 mg/kg; 3040 mL/min: 1.5 mg/kg; 2029 mL/min: 1 mg/kg; <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>Pretreatment: Prehydrate with IV of 1 L NS infused over 12 h immediately before cidofovir infusion. If able to tolerate
            fluid load, infuse second liter over 13 h starting at beginning (or end) of cidofovir infusion.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span>  Dilute the calculated dose in 100 mL of NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Give over 1 h at constant rate.  
               </p>
<ul>
<li>Do not coadminister with other agents with significant nephrotoxic potential.</li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store vials at 20°25° C (68°77° F); may store diluted IV solution at 2°8°
            C (36°46° F) for up to 24 h.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Infection, allergic reactions. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea. <span class="typehead">Metabolic:</span> Metabolic acidosis. <span class="typehead">Hematologic:</span>  Neutropenia. <span class="typehead">CNS:</span>
<span class="speceff-common">Fever, headache,</span> asthenia. <span class="typehead">Respiratory:</span> Dyspnea, pneumonia. <span class="typehead">Special Senses:</span> Ocular hypotony. <span class="typehead">Urogenital:</span>
<span class="speceff-common">Nephrotoxicity, proteinuria.</span>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">aminoglycosides</span>, <b>amphotericin B,</b>
<b>foscarnet,</b>
<b>pentamidine</b> can increase risk of nephrotoxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Duration:</span> Probenecid increases serum levels and area under concentrationtime curve. <span class="typehead">Elimination:</span> 80100% recovered in urine, probenecid delays urinary excretion. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Evaluate concurrent medications. Nephrotoxic drugs are usually discontinued 7 d prior to starting cidofovir.</li>
<li>Lab tests: Baseline and periodic serum creatinine, urine protein; periodic and WBC count with differential prior to each dose.
            Dose adjustments or discontinuation may be required.
         </li>
<li>In patients with proteinuria, administer IV hydration and repeat test.</li>
<li>Periodically monitor visual acuity and intraocular pressure.</li>
<li>Monitor for S&amp;S of hypersensitivity (see Appendix F). Report their appearance promptly.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Those taking zidovudine should discontinue or decrease dose to 50% on days of cidofovir administration.</li>
<li>Initiate or continue regular ophthalmologic exams.</li>
<li>Be alert to potential adverse reactions caused by probenecid (e.g., headache, nausea, vomiting, hypersensitivity reactions)
            and cidofovir.
         </li>
<li>Closely monitor renal function.</li>
<li>Women: Use effective contraception during and 1 mo after treatment.</li>
<li>Men: Use barrier contraception during and 3 mo after treatment.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>